National Research (US:NRC)2024-08-06 21:07Financial Performance - Revenue for Q2 2024 was approximately $35 million, a decrease of 3.2% compared to $36 million in Q2 2023[2] - Earnings per diluted share were $0.26, down from $0.29 in the same quarter last year, representing a decline of 10.3%[2] - Total operating income for Q2 2024 was $8.865 million, down from $9.365 million in Q2 2023, a decrease of 5.3%[10] Contract Value - Total recurring contract value (TRCV) was approximately $138 million as of June 30, 2024[2] Acquisition - The company acquired NOBL Health for an enterprise value of approximately $6 million, with a potential earnout of up to $1 million based on future performance[6] Dividend - The company declared a quarterly cash dividend of $0.12 per share, payable on October 11, 2024[5] Debt and Liabilities - Net indebtedness was approximately $42 million as of June 30, 2024[2] - Total liabilities increased to $78.901 million from $73.482 million as of December 31, 2023[11] Stock Repurchase - The company has approximately 1.1 million shares remaining under its stock repurchase plan[4] Current Assets - Current assets decreased to $16.95 million from $24.36 million as of December 31, 2023[11]